Table 2.
Dynamic disease activity indicators and serum MMP-3 during one year follow-up
| Disease activity indicators | 1st month | 3rd month | 6th month | 12th month |
|---|---|---|---|---|
| 28TJC, median (IQR) | 4 (1 ~ 9)*** | 2 (0 ~ 4)*** | 0 (0 ~ 4)*** | 1 (0 ~ 5)*** |
| 28SJC, median (IQR) | 2 (0 ~ 4)*** | 0 (0 ~ 3)*** | 0 (0 ~ 1)*** | 0 (0 ~ 1)*** |
| Pain VAS, median (IQR) | 2.0 (1.7 ~ 4.0)*** | 2.0 (0 ~ 3.0)*** | 1.0 (0 ~ 2.8)*** | 1.0 (0 ~ 3.0)*** |
| PtGA, median (IQR) | 3.0 (3.0 ~ 5.0)*** | 3.0 (1.0 ~ 4.0)*** | 2.0 (0.3 ~ 3.0)*** | 2.0 (0 ~ 3.8)*** |
| PrGA, median (IQR) | 3.0 (2.3 ~ 4.0)*** | 2.0 (1.0 ~ 4.0)*** | 2.0 (0 ~ 3.0)*** | 2.0 (0 ~ 3.0)*** |
| HAQ, median (IQR) | 0.28 (0 ~ 0.94)*** | 0.15 (0 ~ 0.50)*** | 0 (0 ~ 0.25)*** | 0 (0 ~ 0.46)*** |
| CRP, mg/dl, median (IQR) | 0.44 (0.33 ~ 1.19)*** | 0.33 (0.30 ~ 0.95))*** | 0.34 (0.18 ~ 0.49)*** | 0.33 (0.30 ~ 0.89)*** |
| Normal CRPa, % | 54 | 59 | 77 | 70 |
| ESR, mm/h, median (IQR) | 34 (18 ~ 48)*** | 29 (16 ~ 38)*** | 21 (15 ~ 36)*** | 26 (13 ~ 42)*** |
| Norma ESRb, % | 27 | 38 | 41 | 39 |
| DAS28c, median (IQR) | 3.5 (2.6 ~ 4.4)*** | 2.7 (2.0 ~ 3.9)*** | 2.2 (1.5 ~ 3.2)*** | 2.6 (1.5 ~ 3.3)*** |
| Remission, % | 27 | 43 | 53 | 48 |
| LDA, % | 20 | 20 | 20 | 21 |
| MDA, % | 44 | 30 | 20 | 26 |
| HDA, % | 9 | 7 | 7 | 5 |
| SDAId, median (IQR) | 14.5 (7.6 ~ 24.2)*** | 8.9 (4.1 ~ 17.5)*** | 5.3 (1.0 ~ 12.0)*** | 6.4 (0.3 ~ 12.3)*** |
| Remission, % | 7 | 18 | 39 | 34 |
| LDA, % | 34 | 41 | 36 | 38 |
| MDA, % | 38 | 30 | 16 | 19 |
| HDA, % | 21 | 11 | 9 | 9 |
| CDAIe, median (IQR) | 13.7 (7.1 ~ 22.8)*** | 8.0 (4.0 ~ 15.9)*** | 4.5 (1.0 ~ 11.5)*** | 5.5 (0 ~ 11.0)*** |
| Remission, % | 7 | 18 | 39 | 38 |
| LDA, % | 34 | 45 | 36 | 36 |
| MDA, % | 34 | 26 | 16 | 16 |
| HDA, % | 25 | 11 | 9 | 11 |
| Serum MMP-3, ng/ml, median (IQR) | 112 (49 ~ 347) | 130 (32 ~ 183) | 74 (32 ~ 183)* | 52 (32 ~ 116)*** |
| Normal serum MMP-3f, % | 32 | 38 | 46 | 62 |
| RF, mg/ml, median (IQR) | 119 (39 ~ 252)*** | 72 (20 ~ 169)*** | 49 (14 ~ 137)*** | 78(16 ~ 142)*** |
| Anti-CCP, U/ml, median (IQR) | 85 (11 ~ 300)** | 53 (13 ~ 296)*** | 65 (16 ~ 297)** | 112(14 ~ 300)* |
Pain VAS pain visual analogue scale, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, LDA low disease activity, MDA moderate disease activity, HDA high disease activity, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody
*P < 0.05, **P < 0.01, ***P < 0.001. Compared between each time point and baseline by Wilcoxon matched-pairs signed ranks sum test
anormal CRP: <0.5 mg/dl; bnormal ESR: <20 mm/h (female) or <15 mm/h (male); cDAS28-remission: <2.6; DAS28-LDA:2.6 ~ 3.2, DAS28-MDA:3.2 ~ 5.1, DAS28-HDA:>5.1; dSDAI-remission: <3.3; SDAI-LDA: 3.3 ~ 11.0, SDAI-MDA: 11.0 ~ 26.0, SDAI-HDA: >26.0; eCDAI-remission: <2.8; CDAI-LDA: 2.8 ~ 10.0, CDAI-MDA: 10.0 ~ 22.0, CDAI-HDA: >22.0; fnormal serum MMP-3: <60 ng/ml (female) or <120 ng/ml (male)